We are excited to share that Fusix Biotech was selected to compete in the semi-finals of the 9th edition of EIT Health Catapult. Each year, the competition showcases Europe’s most promising life science and healthtech start-ups to leading experts and investors. The Catapult programme has supported over 330 companies in the eight editions so far, [...]
We are excited to share that Fusix Biotech is the winner of the 2023 Merck Advance Biotech Grant. Fusix Biotech GmbH Biotech led by Dr. Jennifer Altomonte took home the first price, showcasing groundbreaking work that captivated everyone present. Merck understands the challenges emerging biotech companies face in the quest to push the next [...]
We are excited to share that Fusix Biotech is one of winners of the 2023 Nucleate Venture Prize funded by BlueYard Capital. BlueYard’s strategy around biology is based on the premise that humankind’s ability to engineer and understand biology will not only fundamentally transform how we diagnose, treat, and manage disease, but also reinvent [...]
In the Science4Life Venture Cup, Fusix Biotech from Munich convinced the jury. The start-up took third place with its idea of offering patients with difficult-to-treat cancers safe and effective immunotherapeutic therapy approaches with the help of a platform technology. For the first time since 2019, the final awards ceremony of the Science4Life Venture Cup [...]
We are excited to share that Fusix Biotech is one of winners of the Munich Business Plan competition organized by BayStartUP. Phase 1 is focused on the idea and competitive opportunity. Thanks to BayStartUP and all the jurors for the support. The Munich Business Plan Competition is one of the most prestigious awards that [...]
We are grateful for the chance to present at BioM's BioAngels event in front of venture capital investors, business angels and other private investors who invest in life sciences & health tech start-ups. BioAngels is BioM’s exclusive matchmaking event for venture capital investors, business angels and other private investors who invest in life sciences [...]
TUM Faszination Forschung: At the Klinikum rechts der Isar, researchers hope to harness the lethal power of viruses to combat malignant tumors. Jennifer Altomonte and her team are engineering viruses to optimize their therapeutic potential in cancer cells. Part of this therapy concept involves mobilizing specific immune cells. This makes use of a phenomenon [...]
We are proud to announce that PD Dr. Jennifer Altomonte and Dr. Teresa Krabbe from the Klinikum rechts der Isar at the Technical University of Munich have been awarded the M4 Award 2019 for the "Commercialization of oncolytic viruses (Fusix Biotech)". Oncolytic viruses (OVs) now claim a steadily growing market share in cancer therapeutics. [...]
Copyright:
Headquarters
München, Germany
Contact form
Imprint & Data Protection
